GlassScriptPhysician profile
Koushik Sanku
NPI 1710558580
$3,827.80
in general payments reported to CMS, 2019-2025
17 companies · $3,064 in 2025
The $3,064 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $764 · 2025: $3,064.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Travel and Lodging: $887 · Education: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.12 |
| Travel and Lodging | $887.29 |
| Education | $438.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,202.43 | 2024-2025 | Merlin@Home, Gallant, Ensite |
| Boston Scientific Corporation | $760.27 | 2025 | Watchman Flx, Farapulse, Avvigo Guidance System |
| Bayer Healthcare Pharmaceuticals INC. | $187.99 | 2025 | |
| Edwards Lifesciences Corporation | $133.73 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $117.48 | 2025 | Wainua |
| Abiomed | $64.16 | 2024-2025 | Impella |
| Medtronic, INC. | $63.72 | 2025 | Mycarelink |
| Shockwave Medical, INC | $56.24 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Irhythm Technologies, INC. | $39.13 | 2024 | Zio Monitor, Zio Xt Patch |
| Becton, Dickinson and Company | $38.69 | 2025 | Hemosphere |
| Actelion Pharmaceuticals US, INC. | $32.00 | 2025 | Opsumit, Uptravi |
| Cleerly, INC. | $25.00 | 2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $23.11 | 2025 | Camzyos |
| Pfizer INC. | $22.60 | 2025 | |
| Ge Healthcare | $21.58 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.25 | 2025 | |
| Amgen INC. | $18.42 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Koushik Sanku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.